These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 9827615)

  • 1. Unified Huntington's disease rating scale: a follow up.
    Siesling S; van Vugt JP; Zwinderman KA; Kieburtz K; Roos RA
    Mov Disord; 1998 Nov; 13(6):915-9. PubMed ID: 9827615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A shortened version of the motor section of the Unified Huntington's Disease Rating Scale.
    Siesling S; Zwinderman AH; van Vugt JP; Kieburtz K; Roos RA
    Mov Disord; 1997 Mar; 12(2):229-34. PubMed ID: 9087982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.
    Mov Disord; 1996 Mar; 11(2):136-42. PubMed ID: 8684382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The unified Huntington's Disease Rating Scale for advanced patients: validation and follow-up study.
    Youssov K; Dolbeau G; Maison P; Boissé MF; Cleret de Langavant L; Roos RA; Bachoud-Lévi AC
    Mov Disord; 2013 Dec; 28(14):1995-2001. PubMed ID: 24123464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrophysiological deterioration over time in patients with Huntington's disease.
    Lefaucheur JP; Ménard-Lefaucheur I; Maison P; Baudic S; Cesaro P; Peschanski M; Bachoud-Lévi AC
    Mov Disord; 2006 Sep; 21(9):1350-4. PubMed ID: 16721731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of adaptive functioning in Huntington's disease.
    Bylsma FW; Rothlind J; Hall MR; Folstein SE; Brandt J
    Mov Disord; 1993 Apr; 8(2):183-90. PubMed ID: 8474487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional decline in Huntington's disease.
    Feigin A; Kieburtz K; Bordwell K; Como P; Steinberg K; Sotack J; Zimmerman C; Hickey C; Orme C; Shoulson I
    Mov Disord; 1995 Mar; 10(2):211-4. PubMed ID: 7753064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex movement behaviour and progression of Huntington's disease.
    Andrich J; Saft C; Ostholt N; Müller T
    Neurosci Lett; 2007 Apr; 416(3):272-4. PubMed ID: 17321683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unified Huntington's disease rating scale: clinical practice and a critical approach.
    Klempír J; Klempírova O; Spacková N; Zidovská J; Roth J
    Funct Neurol; 2006; 21(4):217-21. PubMed ID: 17367582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bradykinesia in Huntington's disease. A prospective, follow-up study.
    García Ruiz PJ; Hernández J; Cantarero S; Bartolomé M; Sánchez Bernardos V; García de Yébenez J
    J Neurol; 2002 Apr; 249(4):437-40. PubMed ID: 11967649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease.
    Reilmann R; Bohlen S; Klopstock T; Bender A; Weindl A; Saemann P; Auer DP; Ringelstein EB; Lange HW
    Mov Disord; 2010 Oct; 25(13):2195-202. PubMed ID: 20645403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between CAG repeat length and clinical progression in Huntington's disease.
    Ravina B; Romer M; Constantinescu R; Biglan K; Brocht A; Kieburtz K; Shoulson I; McDermott MP
    Mov Disord; 2008 Jul; 23(9):1223-7. PubMed ID: 18512767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Grasping premanifest Huntington's disease - shaping new endpoints for new trials.
    Reilmann R; Bohlen S; Klopstock T; Bender A; Weindl A; Saemann P; Auer DP; Ringelstein EB; Lange HW
    Mov Disord; 2010 Dec; 25(16):2858-62. PubMed ID: 20818671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
    Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
    Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term effects of tetrabenazine on chorea associated with Huntington's disease.
    Kenney C; Hunter C; Davidson A; Jankovic J
    Mov Disord; 2007 Jan; 22(1):10-3. PubMed ID: 17078062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of neuropathological severity in 100 patients with Huntington's disease.
    Rosenblatt A; Abbott MH; Gourley LM; Troncoso JC; Margolis RL; Brandt J; Ross CA
    Ann Neurol; 2003 Oct; 54(4):488-93. PubMed ID: 14520661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlates of early disability in Huntington's disease.
    Mayeux R; Stern Y; Herman A; Greenbaum L; Fahn S
    Ann Neurol; 1986 Dec; 20(6):727-31. PubMed ID: 2949692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of change in early Huntington's disease: a clinicometric analysis.
    Meyer C; Landwehrmeyer B; Schwenke C; Doble A; Orth M; Ludolph AC;
    Mov Disord; 2012 Jan; 27(1):118-24. PubMed ID: 22095693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zotepine in Huntington's disease.
    Bonelli RM; Niederwieser G; Lahousen T; Hofmann P
    Hum Psychopharmacol; 2003 Apr; 18(3):227-9. PubMed ID: 12672176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical measurement of mobility and balance impairments in Huntington's disease: validity and responsiveness.
    Rao AK; Muratori L; Louis ED; Moskowitz CB; Marder KS
    Gait Posture; 2009 Apr; 29(3):433-6. PubMed ID: 19111470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.